IOA-289

Small molecule

IiOnctura

IOA-289 is one of 34 small molecule programs targeting Pancreatic Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Byetta

1 3

ABI-007

Bristol-Myers Squibb

Preclinical

2 4

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 5

Active Comparator

Moderna

Preclinical

1 6

Chemotherapy Agents

Takeda

Preclinical

1 7

Meglitinides

Sanofi

Preclinical

1 8

Secretin-Ferring

Ferring

Preclinical

1 9

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 10

Rybelsus

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ESS1 trial

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

Completed·IiOnctura·Phase 1·NCT05027568·40 enrolled

Pancreatic Cancer1 trial

A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer

Active, not recruiting·IiOnctura·Phase 1/2·NCT05586516·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IOA-289. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IOA-289 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IOA-289. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iOnctura company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IiOnctura

IOA-289

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ESS1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News